Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NICE Draft Negs Tarceva, Alimta For Treatment Of NSCLC

This article was originally published in The Pink Sheet Daily

Executive Summary

Neither Roche's erlotinib or Lilly's pemetrexed represent "good use of scarce" resources, NICE says in preliminary reports.

You may also be interested in...

Roche Appeals Negative EMEA Decision For Tarceva Pancreatic Cancer Indication

EMEA has 60 days to review Tarceva on appeal; the oncologic is approved for treatment of advanced pancreatic cancer in the U.S.

Cancer Drugs Move To NICE's Fast-Track Appraisal Process

Guidances for some products could be issued by the end of the year under a new rapid review system.

Lilly’s Alimta Brochure Does Not Include Specific Indication, Says DDMAC

The firm pulled the patient brochure after receiving an untitled letter from FDA’s ad division.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts